Liquid biopsy-based genomic risk score to predict neurologic death in non-small cell lung cancer patients - Top-Institutions - MDSpire

Liquid biopsy-based genomic risk score to predict neurologic death in non-small cell lung cancer patients

  • By

  • Sarah E. Glynn

  • Ralph D’Agostino Jr

  • Claire M. Lanier

  • Ariel R. Choi

  • Michael Farris

  • Mohammed Abdulhaleem

  • Patrick Young

  • Yuezhu Wang

  • Margaret Smith

  • Jimmy Ruiz

  • Thomas Lycan

  • William Jeffrey Petty

  • Christina K. Cramer

  • Stephen B. Tatter

  • Adrian W. Laxton

  • Jaclyn J. White

  • Jing Su

  • Christopher T. Whitlow

  • Fei Xing

  • Michael D. Chan

  • Corbin A. Helis

  • May 25, 2026

  • 0 min

Share

Top Institutions in Oncology

Brief introduction explaining scope and methodology.

  • #1

    Gustave Roussy
    Gustave Roussy

    Villejuif, France

    Key Differentiators

    • Oncology

  • #2

    Wake Forest School of Medicine
    Wake Forest School of Medicine

    Winston-Salem, North Carolina

    Key Differentiators

    • Oncology

  • #3

    Mayo Clinic
    Mayo Clinic

    Rochester, Minnesota

    Key Differentiators

    • Oncology

Original Source(s)

Liquid biopsy-based genomic risk score to predict neurologic death in non-small cell lung cancer patients

  • by Sarah E. Glynn, Ralph D’Agostino Jr, Claire M. Lanier, Ariel R. Choi, Michael Farris, Mohammed Abdulhaleem, Patrick Young, Yuezhu Wang, Margaret Smith, Jimmy Ruiz, Thomas Lycan, William Jeffrey Petty, Christina K. Cramer, Stephen B. Tatter, Adrian W. Laxton, Jaclyn J. White, Jing Su, Christopher T. Whitlow, Fei Xing, Michael D. Chan, Corbin A. Helis

  • May 25, 2026

Related Content

Predicting 5-Year Mortality in Non–Small-Cell Lung Cancer Using the Korean Central Cancer Registry: Model Development and Validation Study

Glioma management and outcome in low-middle-income countries: a systematic review

Advances in neoadjuvant immunotherapy for non-small cell lung cancer